Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Jurnal Respirasi (JR)

JR
Website

Published by Universitas Airlangga

ISSN : 24070831 EISSN : 26218372 DOI : -

Core Subject : Health,

Health Professions Medicine & Pharmacology Public Health

Jurnal Respirasi is a National journal in accreditation process managed by Department of Pulmonology & Respiratory Medicine Faculty of Medicine Airlangga University - Dr. Soetomo General Hospital, Surabaya. Publish every January, May, September every year with each of 5 (five) complete texts in Indonesian.

Arjuna Subject : -

Articles 321 Documents

17 18 19 20 21

Phantom Tumors in COVID-19: A Case Report Felita Ferdiana; Wayan Wahyu Semara Putra; Velensia Lawrence; Jennifer Mochtar
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Introduction: A phantom tumor, or vanishing lung pseudotumor, is an atypical type of pleural effusion in which fluid is accumulated in the pleural cavity. It is a transient and well-demarcated pleural fluid accumulation in the interlobar pulmonary fissures. In this study, we reported a rare case of a pleural effusion appearing as a phantom tumor in COVID-19 without congestive heart failure. Case: A 29-year-old man was presented with complaints of dry cough, sore throat, fever, and fatigue. He denied shortness of breath and loss of taste and smell. He had no smoking habit and did not have any past medical history. Physical examinations were within normal limits, except for a slight fever. The laboratory examination showed positive SARS-CoV-2 RT-PCR and an increased liver function test. His chest X-ray revealed findings suggestive of a phantom tumor accompanied by bilateral pneumonia. The patient received COVID-19 treatments. A follow-up chest X-ray revealed the complete resolution of the lesion. Conclusion: A phantom tumor is a rare case. It is caused by heart disease and other causes, one of which is COVID-19. The treatment for this condition is based on the underlying disease.

Respiratory Travel Medicine Ni Wayan Candrawati
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

International tourist arrivals continue to increase over time due to global economic growth, increasing middle class in developing countries, technological advances, innovative business concepts, cost-effective travel, and facilitation of visas. The increase in tourist visits has resulted in health problems due to the trips. Respiratory tract infections are the main reason tourists seek medical care. Respiratory infections occur in 20% of all tourists, almost the same as the incidence of diarrhea. The majority of international inbound tourism involved air travel. Though physiological changes happen in everyone while air travel, people with lung disease are at high risk for significant complications and necessitate a specific risk assessment strategy. A pre-flight evaluation is conducted if there is any uncertainty regarding the patient's fitness for flight and the effect of eligibility to fly. This literature review summarized the important aspect of travel medicine from the respiratory medicine point of view.

Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients Vandu Primadana; Indra Yovi; Dyah Siswanti Estiningsih
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Introduction: The regimen of drug-resistant tuberculosis (DR-TB) is Bedaquiline. One of the adverse events is QT interval prolongation, which can increase the risk of Torsade de Pointes (TdP) and lead to death. DR-TB patient screening before starting the treatment and monitoring QT interval during the treatment should be performed. This study aimed to determine Bedaquiline correlation to QT interval prolongation in DR-TB patients. Methods: This was a retrospective study using an observational design by viewing medical records of DR-TB patients who underwent treatment from January 2019 to March 2022. Results: This study involved 46 DR-TB patients with an average age of 41.4 years old, and 58.7% were males with a regimen of Bedaquiline. The comparison of Baseline QT intervals before and after one month of therapy showed QT interval prolongation (457.1 ± 18.2 ms and 443.8 ± 10.2 ms; p < 0.001). The comparison of QT intervals before the therapy and six months after the therapy showed prolongation QT intervals (443.8 ± 10.2 ms and 458.4 ± 23.7 ms; p < 0.001). QT intervals after one month of therapy compared to six months after the therapy showed insignificant slight prolongation (457.1 ± 18.2 ms and 458.4 ± 23.7 ms; p = 0.587). Conclusion: QT interval prolongation occurred in DR-TB patients who received treatment using Bedaquiline regimen. It was seen significantly between baseline QT interval and after receiving the therapy for one month and six months.

Prognostic Value of the Systemic Immune-Inflammation Index in EGFR Mutation-Positive Lung Adenocarcinoma Patients Treated with Tyrosine Kinase Inhibitors Marsheilla Riska; Haryati Haryati; Eko Suhartono; Tenri Ashari Wanahari
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Introduction: Inflammatory parameters calculated from complete blood counts such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII) are related to poor prognosis in lung cancer patients. This study aimed to explore a correlation between NLR, PLR, and SII to survival rates in advanced lung adenocarcinoma with tyrosine kinase inhibitors (TKIs) as the main treatment choice. Methods: This was a retrospective observational study of patients with epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma treated by TKIs at Ulin General Hospital Banjarmasin from January 2017 to December 2019. The optimal cut-off values for NLR, PLR, and SII were obtained using the receiver operating characteristic curve (ROC). Kaplan–Meier analyses were used to assess the prognostic value of inflammation parameters in overall survival (OS) and progression-free survival (PFS). Results: This study involved 50 samples, 62% male, with an average age of 55.98 years old, 94% in stage IVA, EGFE mutation in exon 19 (58%) and exon 21 (42%). About 58% of patients have a smoking history. The optimal cut-off value for NLR, PLR, and SII was 6.095, 356.935, and 1767.0, respectively. However, only the SII was significantly associated with survival; SII ≥ 1767.0 correlated with shorter OS (18 months vs. 28 months, p = 0.014) and PFS (7 months vs. 12 months, p = 0.004). Conclusion: Pre-treatment SII can be a prognostic factor for survival in EGFR mutation-positive lung adenocarcinoma patients receiving TKIs.

Challenging Treatment of Drug-Resistant Tuberculosis during Pregnancy: A Case Report Ni Luh Putu Eka Arisanti; Ni Putu Ayu Widiasari; Ni Wayan Candrawati; Ida Ayu Jasminarti Dwi Kusumawardani; Ida Bagus Ngurah Rai; Made Ary Sarasmita
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Introduction: Globally, drug-resistant tuberculosis (TB) still has a high number of cases. Pregnant women are one of the high-risk populations for TB infection, especially multidrug resistance (MDR)/Rifampicin resistance (RR) TB. Physiological differences in pregnant women and the safety of the fetus make drug resistance TB treatment challenging. Case: A 20-year-old woman was 22 weeks pregnant while undergoing the third month of the late phase for short-regimen. Thus, Kanamycin was one of her early phase treatment combinations during the first trimester of pregnancy. After we consulted with other departments, especially the obstetric department, we decided not to change her regimen. Her chief complaint before treatment was cough with white sputum and fluctuated shortness of breath for two months. The patient only experienced minor side effects in the early treatment phase. The patient was cured of MDR TB on 8 October 2020 at 34 weeks of gestation. Her baby was born on 10 November 2020 at 37 weeks without congenital abnormality. Observation for her baby continued by the pediatric department. The last follow-up of her baby in the middle of 2022 found no abnormality in the child’s growth and development. Conclusion: Drug-resistant TB therapy in pregnant women requires the collaboration of a multidisciplinary team to consider the benefits and risks of the therapy based on gestational age and disease severity.

Lung Abscess as a Delayed Complication in a COVID-19 Pneumonia Patient: A Case Report Indah Rahmawati; Regia Anadhia Pinastika; Raditya Bagas Wicaksono
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Introduction: In March 2020, the World Health Organization (WHO) proclaimed coronavirus disease 2019 (COVID-19) a global pandemic. Indonesia is one of the nations that is still dealing with the COVID-19 outbreak. COVID-19 has several complications, including lung abscesses in extremely rare cases. We presented the first reported COVID-19 patient in Indonesia with a delayed lung abscess. Case: A 30-year-old man presented to the hospital with breathlessness and tested positive for COVID-19. Chest X-ray revealed typical COVID-19 pneumonia. He was discharged after 16 days of hospitalization and was educated on using oxygen at home lest the breathlessness recurred. We planned to evaluate the patient’s chest X-ray after 2 weeks of discharge. The follow-up chest X-ray revealed an air-fluid level in the upper lobe of the right lung, indicating a lung abscess. The patient was treated with antibiotics for 2–3 weeks. Clinical follow-up 4 weeks after the treatment revealed no symptoms, and chest X-ray showed significant improvement. Conclusion: Lung abscess is one of the rare complications of COVID-19. A pulmonary infection creates an air-fluid level by forming a cavity in the lung parenchyma. Notably, this complication manifested 2 weeks after the patient was discharged. COVID-19 can have several unexpected complications, including lung abscesses. It is crucial to monitor patients after discharge for such complications, especially if they are symptomatic.

Role of Nintedanib in COVID-19-Related Lung Fibrosis Alif Fathurrachman; Linda Andriani; Rouly Pasaribu; Sudarto Sudarto; Ahmad Rasyid; Zen Ahmad; Tommy Setiawan
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

In December 2020, Indonesia was introduced to the long Coronavirus disease 2019 (COVID-19) phenomenon. The Centers for Disease Control and Prevention (CDC) introduced the term "post-COVID condition" as a health problem that persists after four weeks from the first exposure to COVID-19. The National Institute for Healthcare and Care Excellence (NICE) classifies COVID-19 infections into three categories based on disease duration: (1) acute infection for up to 4 weeks; (2) ongoing infection within 4-12 weeks; and (3) post-COVID-19 syndrome for more than 12 weeks and not associated with an alternative diagnosis. One of these phenomena is lung fibrosis. About 80% of COVID-19 survivors had mild to severe chest X-rays in 6 months of follow-up with decreasing lung function. COVID-19-related lung fibrosis is still not widely researched. COVID-19 survivors who develop lung fibrosis usually recover independently, but some develop persistent lung fibrosis. The use of antifibrotic agents, such as nintedanib, has long been approved for idiopathic pulmonary fibrosis (IPF). However, its use in the cases of lung fibrosis due to COVID-19 has not been widely studied. Nintedanib is a tyrosine kinase inhibitor. It inhibits receptor activity of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). Those actions will eventually inhibit the proliferation, migration, and transformation of fibroblasts into myofibroblasts in lung fibrogenesis. Therefore, an antifibrotic agent is potentially needed to inhibit COVID-19-related lung fibrosis to improve quality of life and prevent further lung damage.

Front Matter Vol 8 No 3, 2022 Front Matter
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1054.329 KB)

Back Matter Vol 8 No 3, 2022 Back Matter
Jurnal Respirasi Vol. 8 No. 3 (2022): September 2022
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (395.517 KB)

Prevalence and Risk Factors of GERD among Stable COPD Patients Muhammad Hafiz; Faisal Yunus; Maulana Suryamin; Mohammad Fahmi Alatas; Adityo Wibowo
Jurnal Respirasi Vol. 9 No. 1 (2023): January 2023
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v9-I.1.2023.1-6

Introduction: Gastroesophageal reflux disease (GERD) is one of the most common causes of a chronic cough and is a potential risk factor for chronic obstructive pulmonary disease (COPD) exacerbation. This study aimed to determine the prevalence of GERD in COPD patients. Methods: This was a cross-sectional study involving 40 stable COPD patients recruited from outpatient asthma and COPD clinics at Persahabatan National Respiratory Referral Hospital, Jakarta, from May to November 2018. COPD was defined as having a ratio of post-bronchodilator FEV1/FVC < 0.7 and no abnormality on a chest X-ray except emphysematous. Diagnosis of GERD was based on oesophageal mucosal lining break surrounding the distal esophageal sphincter through esophagogastroduodenoscopy (EGD). Asthma patients with known esophageal diseases such as cancer, achalasia, and active peptic ulcer and patients who had used proton pump inhibitors in the last 15 days were excluded. Results: Patients were divided into GERD (+) (16/40, 40%) and GERD (-) (24/40, 60%). Subjects were predominantly elderly (25/40, 62.5%) and had a smoking history (36/40, 90%). Exacerbation and COPD assessment test (CAT) score was significantly associated with GERD (p < 0.05). No significant difference regarding age, sex, Brinkman Index, lung function, and body mass index (BMI) was found between groups. However, the GERD (+) group showed a slightly higher BMI and more severe airflow obstruction. Conclusion: The prevalence of GERD in COPD patients found in this study was as high as 40%. A cohort study and preventive strategy of GERD in COPD should be studied further.

Page 19 of 33 | Total Record : 321

17 18 19 20 21

Filter by Year

2015 2025

Filter By Issues

All Issue Vol. 11 No. 3 (2025): September 2025 Vol. 11 No. 2 (2025): May 2025 Vol. 11 No. 1 (2025): January 2025 Vol. 10 No. 3 (2024): September 2024 Vol. 10 No. 2 (2024): May 2024 Vol. 10 No. 1 (2024): January 2024 Vol. 9 No. 3 (2023): September 2023 Vol. 9 No. 2 (2023): May 2023 Vol. 9 No. 1 (2023): January 2023 Vol. 8 No. 3 (2022): September 2022 Vol. 8 No. 2 (2022): May 2022 Vol. 8 No. 1 (2022): January 2022 Vol. 7 No. 3 (2021): September 2021 Vol. 7 No. 2 (2021): May 2021 Vol. 7 No. 1 (2021): January 2021 Vol. 6 No. 3 (2020): September 2020 Vol. 6 No. 2 (2020): May 2020 Vol. 6 No. 1 (2020): January 2020 Vol. 5 No. 3 (2019): September 2019 Vol. 5 No. 2 (2019): Mei 2019 Vol. 5 No. 1 (2019): Januari 2019 Vol. 4 No. 3 (2018): September 2018 Vol. 4 No. 2 (2018): Mei 2018 Vol. 4 No. 1 (2018): Januari 2018 Vol. 3 No. 3 (2017): September 2017 Vol. 3 No. 2 (2017): Mei 2017 Vol. 3 No. 1 (2017): Januari 2017 Vol. 2 No. 3 (2016): September 2016 Vol. 2 No. 2 (2016): Mei 2016 Vol. 2 No. 1 (2016): Januari 2016 Vol. 1 No. 3 (2015): September 2015 Vol. 1 No. 2 (2015): Mei 2015 Vol. 1 No. 1 (2015): Januari 2015 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
-

Contact Email
-

Phone
-

Journal Mail Official
respirasi@journal.unair.ac.id

Editorial Address
Jl. Mayjen Prof. Dr. Moestopo 6-8 Surabaya 60286 Indonesia

Location
Kota surabaya,

Jawa timur

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name -

Contact Email -

Phone -

Journal Mail Official respirasi@journal.unair.ac.id

Editorial Address Jl. Mayjen Prof. Dr. Moestopo 6-8 Surabaya 60286 Indonesia

Location Kota surabaya, Jawa timur INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
-

Contact Email
-

Phone
-

Journal Mail Official
respirasi@journal.unair.ac.id

Editorial Address
Jl. Mayjen Prof. Dr. Moestopo 6-8 Surabaya 60286 Indonesia

Location
Kota surabaya,

Jawa timur

INDONESIA